Arcturus Therapeutics Ltd.

Industry

  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
      • Pulmonary

Other Names/Subsidiaries

  • Alcobra
  • Alcobra Pharma
  • Arcturus Therapeutics
See more in Biomedtracker

Latest on Arcturus Therapeutics Ltd.

Scrip

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Arcturus Therapeutics and licensing partner CSL have got approval in the EU for Kostaive, a self-amplifying mRNA (sa-mRNA) vaccine that the firms hope will become a major product in the COVID-19 space

Pink Sheet

Vaccine Misinformation: Meiji Considers Legal Action Amid Japan Launch Of Kostaive

 
• By Lisa Takagi

A self-amplifying mRNA vaccine for COVID-19, Arcturus Therapeutics’ Kostaive (ARCT-154), has been the subject of extensive disparaging and scientifically inaccurate comments online in its first market

Scrip

Deal Watch: Merck KGaA Enhances Cell/Gene Therapy Capabilities With Mirus Takeout

 
• By Joseph Haas, Vibha Ravi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck KGaA Pays $600m For Transfection

Scrip

Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma

 
• By Joseph Haas, Lisa Takagi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. SNBL To Pay 28% Premium To Re-Acquire S